Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients wiht essential hypertension

Hypertension Research

Volumn 29, Issue 5, 2006, Pages 339-344

  Yamagishi, Toshio ^a  

^a TOHOKU ROSAI HOSPITAL   (Japan)

Author keywords

Clinidipine; Home blood pressure; Morning hypertension; N type calcium channel; White coat effect

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; ESSENTIAL HYPERTENSION; FEMALE; HOME MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRESCRIPTION; WHITE COAT HYPERTENSION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNELS; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OFFICE VISITS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33745661186     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.339     Document Type: Article

References (29)

1. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.
2. Ohkubo T, Imai Y, Tsuji I, et al: Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971-975.
3. Bobrie G, Chatellier G, Genes N, et al: Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-management in elderly treated hypertensive patients. JAMA 2004; 291: 1342-1349.
4. White WB: Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6: 63-72.
5. Imai Y, Otsuka K, Kawano Y, et al: Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771-782.
6. Tominaga M, Ohya Y, Tsukashima A, et al: Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc Drugs Ther 1997; 11: 43-48.
7. Kitahara Y, Saito F, Akao M, et al: Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. J Cardiovasc Pharmacol 2004; 43: 68-73.
8. Ohkubo T, Obara T, Funahashi J, et al: Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res 2004; 27: 755-763.
9. Obara T, Ohkubo T, Funahashi J, et al: Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study. J Hypertens 2005; 23: 1653-1660.
10. White WB: Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21: S9-S15.
11. Kumagai Y: Strategies against high blood pressure in the early morning. Clin Exp Hypertens 2004; 26: 107-118.
12. Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of telmisartan for decreasing home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545-550.
13. Yoshimoto R, Dohmoto H, Yamada K, Goto A: Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4-dihydropyridine calcium antagonist cilnidipine (FRC-8653). Jpn J Pharmacol 1991; 56: 225-229.
14. Hosono M, Iida H, Ikeda K, et al: In vitro and ex vivo Caantagonistic effect of 2-methoxyethyl(E)-3-phenyl-2-propen-1-y1±-1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate (FRC-8653), a new dihydropyridine derivative. J Pharmacobiodyn 1992; 15: 547-553.
15. Nakajima M, Yamada S, Uchida S, Kimura R: In vitro measufrement of 1,4-dihydropyridine receptors in mesenteric arteries of spontaneously hypertensive rats and effect of nifedipine and cilnidipine. Biol Pharm Bull 2002; 25: 24-28.
16. Weber MA: The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am J Cardiol 2002; 89: 27A-33A.
17. Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
18. Kamoi K, Ikarashi T: The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. Clin Exp Hypertens 2005; 27: 369-376.
19. Chrysant SG, Chrysant GS, Desai A: Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 2005; 19: 173-183.
20. Ide H, Tsutsumi T, Takeyama Y, Osada H: Actions of calcium antagonists on circadian systolic blood pressure rhythm and autonomic function in hypertensive patients. Jpn J Clin Pharmacol Ther 2004; 35: 1-8.
21. Kario K, James GD, Marion R, Ahmed M, Pickering TG: The influence of work- and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women. Hypertens Res 2002; 25: 499-506.
22. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P: Task force V: white-coat hypertension. Blood Press Monit 1999; 4: 333-341.
23. Kumpusalo E, Teho A, Laitila R, Takala J: Janus faces of the white coate effect: blood pressure not only rises, it may also fall. J Hum Hypertens 2002; 16: 725-728.
24. Mulè G, Nardi E, Cottone S, et al: Relationships between ambulatory white coat effect and left ventricular mass in arterial hypertension. Am J Hypertens 2003; 16: 498-501.
25. Munakata M, Saito Y, Nunokawa T, Ito N, Fukudo S, Yoshinaga K: Clinical significance of blood pressure response triggered by a doctor's visit in patients with essential hypertension. Hypertens Res 2002; 25: 343-349.
26. Strandberg TE, Salomaa V: White coat effect, blood pressure and mortality in men: prospective cohort study. Eur Heart J 2000; 21: 1714-1718.
27. Sakaki T, Naruse H, Masai M, et al: Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzylguanidine imaging in rat hearts. Ann Nucl Med 2003; 17: 321-326.
28. Sakata K, Yoshida H, Obayashi K, et al: Comparative effect of cilnidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res 2003; 29: 117-123.
29. Nagai H, Minatoguchi S, Chen XH, et al: Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction. Hypertens Res 2005; 28: 361-368.